Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles ImmuCell Corporation’s (Nasdaq: ICCC) SEC filings, giving investors structured access to the company’s regulatory disclosures as an animal health business focused on dairy and beef cattle. ImmuCell’s filings include current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, along with other exhibits and agreements.
Through these documents, readers can review ImmuCell’s reported product sales for its First Defense® line, commentary on trends in domestic and international sales, and management’s discussion of gross margins, net income or loss, and backlog dynamics. Filings also describe the development status of Re-Tain®, including the New Animal Drug Application process, investigational product use, and the company’s decision to pause further direct investment after receiving an FDA Incomplete Letter related to a contract manufacturer.
ImmuCell’s SEC reports provide detail on financing arrangements, such as loan agreements and lines of credit with Maine Community Bank, refinancing transactions, and related security interests in company assets. They also disclose corporate governance and leadership changes, including CEO succession, board expansion, and executive employment agreements, as well as other material definitive agreements.
On Stock Titan, these filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain lengthy 10-K and 10-Q reports, highlight key risk factors and business updates, and clarify the implications of Form 8-K events. Users can also quickly identify information about executive and board changes, financing obligations and other material developments affecting ImmuCell’s cattle health-focused operations.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.